Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2022 - 2025)
Historic Total Non-Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $321000.0.
- Corvus Pharmaceuticals' Total Non-Current Liabilities fell 4864.0% to $321000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $321000.0, marking a year-over-year decrease of 4864.0%. This contributed to the annual value of $593000.0 for FY2024, which is 848.77% down from last year.
- Per Corvus Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $321000.0 for Q3 2025, which was down 4864.0% from $414000.0 recorded in Q2 2025.
- Corvus Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $1.0 million during Q2 2022, with a 5-year trough of $321000.0 in Q3 2025.
- Its 4-year average for Total Non-Current Liabilities is $681857.1, with a median of $636500.0 in 2023.
- As far as peak fluctuations go, Corvus Pharmaceuticals' Total Non-Current Liabilities crashed by 848.77% in 2024, and later tumbled by 4864.0% in 2025.
- Over the past 4 years, Corvus Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $985000.0 in 2022, then tumbled by 34.21% to $648000.0 in 2023, then fell by 8.49% to $593000.0 in 2024, then tumbled by 45.87% to $321000.0 in 2025.
- Its Total Non-Current Liabilities was $321000.0 in Q3 2025, compared to $414000.0 in Q2 2025 and $503000.0 in Q1 2025.